FDA Approves Elitek (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
Links shared publicly online about this topic.
- 1,665total visits
FDA Approves Elitek (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
View full resource at drugs.com
Tags: Cancer, Chemotherapy, Leukemia, Lymphoma, FDA
Most Recently Shared on October 19, 2009 at 11:24 pm By:
FDA Approves Elitek (rasburicase) for Management of Hyperuricemia in Adults Receiving Chemotherapy - http://bit.ly/3ifMlA
Elitek approved for management of plasma uric acid levels in cancer patients - MPR
empr.com — “Elitek (rasburicase, from sanofi-aventis), a recombinant urate oxidase enzyme, has been approved for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.” View full resource at empr.com
Most Recently Shared on October 19, 2009 at 4:40 pm By:
MPR News: Elitek approved for management of plasma uric acid levels in cancer patients : Elitek (rasbur.. http://bit.ly/3WwcV
Advertisement
